600422 昆药集团
交易中 05-06 10:09:05
资讯
新帖
简况
北向资金4月29日净买入昆药集团1.65万股 连续3日增持
自选股智能写手 · 04-30
北向资金4月29日净买入昆药集团1.65万股 连续3日增持
昆药集团: 昆药集团财务共享中心成立于2021年,目前处于稳定、成熟期
证券之星 · 04-26
昆药集团: 昆药集团财务共享中心成立于2021年,目前处于稳定、成熟期
青蒿素概念盘中拉升,昆药集团涨1.36%
自选股智能写手 · 04-26
青蒿素概念盘中拉升,昆药集团涨1.36%
昆药集团获华源证券买入评级,华润赋能初见成效
金融界 · 04-25
昆药集团获华源证券买入评级,华润赋能初见成效
华源证券给予昆药集团买入评级 华润赋能初见成效 聚焦银发经济潜力可期
每日经济新闻 · 04-25
华源证券给予昆药集团买入评级 华润赋能初见成效 聚焦银发经济潜力可期
华源证券:给予昆药集团买入评级
证券之星 · 04-25
华源证券:给予昆药集团买入评级
北向资金4月24日净卖出昆药集团52.34万股 连续3日减持
自选股智能写手 · 04-25
北向资金4月24日净卖出昆药集团52.34万股 连续3日减持
昆药集团(600422)4月23日主力资金净卖出321.49万元
证券之星 · 04-24
昆药集团(600422)4月23日主力资金净卖出321.49万元
昆药集团(600422)经营质量稳步提升,扣非增长符合预期
中信建投 · 04-23
昆药集团(600422)经营质量稳步提升,扣非增长符合预期
青蒿素概念盘中拉升,昆药集团涨3.30%
自选股智能写手 · 04-23
青蒿素概念盘中拉升,昆药集团涨3.30%
北向资金4月19日净买入昆药集团30.57万股 连续7日增持
自选股智能写手 · 04-22
北向资金4月19日净买入昆药集团30.57万股 连续7日增持
昆药集团股价创1月新低 一季度净利同比下降9.41%
智选洞察 · 04-22
昆药集团股价创1月新低 一季度净利同比下降9.41%
昆药集团一季度净利下滑9.86% 营收18.53亿同比减3.01%
和讯网 · 04-22
昆药集团一季度净利下滑9.86% 营收18.53亿同比减3.01%
华润三九(000999)2024年一季报点评:业绩超预期,内生增长强劲
浙商证券 · 04-22
华润三九(000999)2024年一季报点评:业绩超预期,内生增长强劲
【港股通】华润医药(03320):昆药集团首季净利润1.21亿元人民币 同比减少10%
金吾财讯 · 04-22
【港股通】华润医药(03320):昆药集团首季净利润1.21亿元人民币 同比减少10%
昆药集团获东吴证券买入评级,“昆中药1381”品牌打造初见成效
金融界 · 04-21
昆药集团获东吴证券买入评级,“昆中药1381”品牌打造初见成效
东吴证券:给予昆药集团买入评级
证券之星 · 04-21
东吴证券:给予昆药集团买入评级
东吴证券给予昆药集团买入评级 2024一季报点评 近期获11份券商研报关注 目标均价涨幅15.01%
每日经济新闻 · 04-21
东吴证券给予昆药集团买入评级 2024一季报点评 近期获11份券商研报关注 目标均价涨幅15.01%
图解昆药集团一季报:第一季度单季净利润同比减9.41%
证券之星 · 04-20
图解昆药集团一季报:第一季度单季净利润同比减9.41%
昆药集团:2024年第一季度净利润约1.19亿元
每日经济新闻 · 04-19
昆药集团:2024年第一季度净利润约1.19亿元
公司概况
公司名称:
昆药集团股份有限公司
所属行业:
医药制造业
上市日期:
2000-12-06
主营业务:
昆药集团股份有限公司主要从事药物研发、生产及销售、医药流通及大健康产业。公司新增国内授权发明专利9件、外观专利6件、PCT发明专利1件。公司“集团财务业务一体化管控能力”项目入选2022年工信部新一代信息技术与制造业融合发展试点示范名单。中国药店杂志社主办的2022-2023中国药店发展报告暨中国药店价值榜发布会上,昆药血塞通软胶囊、昆中药参苓健脾胃颗粒、昆中药舒肝颗粒、贝克诺顿阿莫西林荣获“2022年度中国药店店员推荐率最高品牌”奖项。中国中药协会主办的中国中药产业高质量发展论坛暨第三届中国中药品牌建设大会上,公司荣登“2022中成药企业百强榜”位列第13位,“2022中药上市公司TOP30”位列第12位。昆中药博物馆(非遗体验馆)荣获“春融同心·昆明市统战文化基地”称号;子公司上海昆恒医药科技有限公司认定为上海市“专精特新”中小企业。昆药血塞通软胶囊、昆中药参苓健脾胃颗粒荣获2023乌镇健康大会西湖奖,最受药店欢迎的明星单品奖。公司再次获得由国家认证认可监督管理委员会批准,中健安检测认证中心颁发的三七道地药材认证证书;子公司昆中药顺利通过知识产权管理体系贯标再认证(知识产权贯标是指贯彻《企业知识产权管理规范》(GB/T29490-2013)这一知识产权管理的国家标准),位列“2023年度云南省创新管理知识产权国际标准实施试点企业名单”。
发行价格:
10.22
{"stockData":{"symbol":"600422","market":"SH","secType":"STK","nameCN":"昆药集团","latestPrice":23.08,"timestamp":1714961345000,"preClose":22.72,"halted":0,"volume":2525500,"delay":0,"floatShares":757000000,"shares":757000000,"eps":0.5711,"marketStatus":"交易中","marketStatusCode":2,"change":0.36,"latestTime":"05-06 10:09:05","open":22.91,"high":23.13,"low":22.4,"amount":57506800,"amplitude":0.0321,"askPrice":23.07,"askSize":10,"bidPrice":23.05,"bidSize":8,"shortable":0,"etf":0,"ttmEps":0.5711,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1714966200000},"adr":0,"adjPreClose":22.72,"symbolType":"stock","openAndCloseTimeList":[[1714959000000,1714966200000],[1714971600000,1714978800000]],"highLimit":24.99,"lowLimit":20.45,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":757113997,"pbRate":3.18,"roa":"--","roe":"2.22%","epsLYR":0.59,"committee":0.584296,"marketValue":17474000000,"floatMarketCap":17471000000,"peRate":40.413238,"changeRate":0.0158,"turnoverRate":0.0033,"status":0},"requestUrl":"/m/hq/s/600422/wiki","defaultTab":"wiki","newsList":[{"id":"2431804073","title":"北向资金4月29日净买入昆药集团1.65万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2431804073","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431804073?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:30","pubTimestamp":1714440612,"startTime":"0","endTime":"0","summary":"4月29日, 北向资金增持昆药集团1.65万股,连续3日增持。截止当日收盘,沪股通共持有昆药集团1083.15万股,占流通股1.43%。沪股通增持金额前五个股分别为江苏银行、陕西煤业、宇通客车、三一重工、韦尔股份。昆药集团近5个交易日上涨9.48%,沪股通累计增持46.08万股;近20个交易日上涨8.18%,沪股通累计增持285.22万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300931348b642662&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300931348b642662&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430227390","title":"昆药集团:\n昆药集团财务共享中心成立于2021年,目前处于稳定、成熟期","url":"https://stock-news.laohu8.com/highlight/detail?id=2430227390","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430227390?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:01","pubTimestamp":1714129296,"startTime":"0","endTime":"0","summary":"证券之星消息,昆药集团04月26日在投资者关系平台上答复投资者关心的问题。如果按照初建期,提升期,稳定期,成熟期,卓越期和衰退期来描述财务共享实施的阶段,您认为是在哪一阶段?期待您的回答,感谢昆药集团董秘:尊敬的投资者,您好。昆药集团财务共享中心成立于2021年,目前处于稳定、成熟期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600047488.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430029844","title":"青蒿素概念盘中拉升,昆药集团涨1.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430029844","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430029844?lang=zh_cn&edition=full","pubTime":"2024-04-26 09:38","pubTimestamp":1714095493,"startTime":"0","endTime":"0","summary":"04月26日,青蒿素概念盘中拉升,截至09点38分,青蒿素概念整体指数上涨0.55%,报1102.870点。从个股上来看,该概念的成分股中,昆药集团涨1.36%,海正药业、新 和 成、复星医药涨幅居前。从资金上来看,截止发稿,青蒿素概念主力净流入为-430.64万,其中华润双鹤受到资金热捧,主力净流入503.37万;拉长时间线来看,该板块近20日主力资金净流入-5.67亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240426093813861e93b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240426093813861e93b8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430309476","title":"昆药集团获华源证券买入评级,华润赋能初见成效","url":"https://stock-news.laohu8.com/highlight/detail?id=2430309476","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430309476?lang=zh_cn&edition=full","pubTime":"2024-04-25 17:14","pubTimestamp":1714036475,"startTime":"0","endTime":"0","summary":"4月25日,昆药集团获华源证券买入评级,近一个月昆药集团获得3份研报关注。研报认为,昆药集团正式完成董监事会改组,华润三九成为公司控股股东,由原华润三九OTC事业部总经理颜炜担任副董事长、党委书记及总裁。公司制定五年战略发展规划,昆药集团聚焦精品国药、老龄健康-慢病管理两大核心业务领域,致力于成为“老龄健康-慢病管理领域领导者”和“精品国药领先者”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042517144187ae8166&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042517144187ae8166&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430732284","title":"华源证券给予昆药集团买入评级 华润赋能初见成效 聚焦银发经济潜力可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2430732284","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430732284?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:41","pubTimestamp":1714034480,"startTime":"0","endTime":"0","summary":"华源证券04月25日发布研报称,给予昆药集团(600422.SH,最新价:22元)买入评级。评级理由主要包括:1)深耕三七产业链,战略定位银发经济;2)六百余年昆中药,打造精品国药领先者。风险提示:中药行业政策风险;产品销售不及预期风险;研发进度不及预期风险;原材料价格波动风险。AI点评:昆药集团近一个月获得6份券商研报关注,买入4家。文章来源:每日经济新闻原标题:华源证券给予昆药集团买入评级,华润赋能初见成效,聚焦银发经济潜力可期","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042516591487ae7108&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042516591487ae7108&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430478681","title":"华源证券:给予昆药集团买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2430478681","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430478681?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:36","pubTimestamp":1714034172,"startTime":"0","endTime":"0","summary":"华源证券股份有限公司刘闯近期对昆药集团进行研究并发布了研究报告《华润赋能初见成效,聚焦银发经济潜力可期》,本报告对昆药集团给出买入评级,当前股价为22.0元。 昆药集团 华润入主融合顺利,五年战略规划谱写新篇章。首次覆盖,给予“买入”评级。最新盈利预测明细如下:该股最近90天内共有15家机构给出评级,买入评级12家,增持评级3家;过去90天内机构目标均价为24.2。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500033393.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430414001","title":"北向资金4月24日净卖出昆药集团52.34万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2430414001","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430414001?lang=zh_cn&edition=full","pubTime":"2024-04-25 09:30","pubTimestamp":1714008611,"startTime":"0","endTime":"0","summary":"4月24日,北向资金减持昆药集团52.34万股连续3日减持。截止当日收盘,沪股通共持有昆药集团946.98万股,占流通股1.25%。沪股通减持金额前五个股分别为兆易创新、中微公司、金山办公、江苏银行、国电南瑞。昆药集团近5个交易日下跌1.32%,沪股通累计减持102.11万股;近20个交易日上涨0.33%,沪股通累计增持54.49万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042509313387acecb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042509313387acecb5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429124381","title":"昆药集团(600422)4月23日主力资金净卖出321.49万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429124381","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429124381?lang=zh_cn&edition=full","pubTime":"2024-04-24 07:44","pubTimestamp":1713915885,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年4月23日收盘,昆药集团报收于21.59元,上涨3.35%,换手率1.63%,成交量12.37万手,成交额2.65亿元。近5日资金流向一览见下表:昆药集团融资融券信息显示,融资方面,当日融资买入621.4万元,融资偿还1515.09万元,融资净偿还893.69万元。昆药集团主营业务:药物研发、生产及销售等领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400013298.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429131753","title":"昆药集团(600422)经营质量稳步提升,扣非增长符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2429131753","media":"中信建投","top":-1,"share":"https://www.laohu8.com/m/news/2429131753?lang=zh_cn&edition=full","pubTime":"2024-04-23 11:13","pubTimestamp":1713842039,"startTime":"0","endTime":"0","summary":"事件公司发布2024年一季度报告4月19日晚,公司发布2024年一季度报告,实现营业收入、归母净利润和扣非后净利润分别为18.53亿元、1.19亿元和1.13亿元,分别同比增长-3.01%、-9.41%和9.11%,实现每股收益0.16元,业绩增长符合我们此前预期。总体来看,预计公司工业板块在行业外部环境影响下短期承压,商业板块在低基数下实现逐步恢复,经营质量稳步提升带动主业利润增长,整体业绩符合预期。公司经营质量实现持续改善,其余财务指标基本正常。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042311493887a40f65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042311493887a40f65&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429892180","title":"青蒿素概念盘中拉升,昆药集团涨3.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429892180","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429892180?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:50","pubTimestamp":1713837054,"startTime":"0","endTime":"0","summary":"04月23日,青蒿素概念盘中拉升,截至09点50分,青蒿素概念整体指数上涨1.11%,报1080.660点。从个股上来看,该概念的成分股中,昆药集团涨3.30%,新 和 成、德龙汇能、润都股份涨幅居前。从资金上来看,截止发稿,青蒿素概念主力净流入为529.05万,其中复星医药受到资金热捧,主力净流入335.94万;拉长时间线来看,该板块近20日主力资金净流入-4.31亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404230950547a54b5c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404230950547a54b5c5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429596195","title":"北向资金4月19日净买入昆药集团30.57万股 连续7日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2429596195","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429596195?lang=zh_cn&edition=full","pubTime":"2024-04-22 09:30","pubTimestamp":1713749412,"startTime":"0","endTime":"0","summary":"4月19日, 北向资金增持昆药集团30.57万股,连续7日增持。截止当日收盘,沪股通共持有昆药集团1081.84万股,占流通股1.42%。沪股通增持金额前五个股分别为万华化学、中信证券、珀莱雅、华阳股份、平煤股份。昆药集团近5个交易日下跌1.88%,沪股通累计增持179.92万股;近20个交易日上涨3.18%,沪股通累计增持199.77万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404220931128b43ada7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404220931128b43ada7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429961954","title":"昆药集团股价创1月新低 一季度净利同比下降9.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429961954","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2429961954?lang=zh_cn&edition=full","pubTime":"2024-04-22 09:30","pubTimestamp":1713749407,"startTime":"0","endTime":"0","summary":"昆药集团4月19日晚间发布一季度业绩公告称,2024年第一季度营收约18.53亿元,同比减少3.01%;归属于上市公司股东的净利润约1.19亿元,同比减少9.41%;基本每股收益0.16元,同比减少5.88%。最新财报显示,今年一季报,昆药集团实现营业收入18.53亿元,同比减少3.01%,净利润为1.19亿元,同比减少9.41%,基本每股收益为0.16元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404220934437a545a2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404220934437a545a2c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429496471","title":"昆药集团一季度净利下滑9.86% 营收18.53亿同比减3.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429496471","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2429496471?lang=zh_cn&edition=full","pubTime":"2024-04-22 09:26","pubTimestamp":1713749193,"startTime":"0","endTime":"0","summary":"步骤3:整合为快讯 昆药集团一季度营业收入和净利润均出现下滑,分别同比减少3.01%和9.86%,主要受市场竞争和成本压力影响。快讯正文华润医药宣布昆药集团一季度净利下滑9.86% 华润医药日前发布公告,该公司附属昆药集团截至2024年3月31日止3个月实现营业收入18.53亿元,同比减少3.01%;净利润1.21亿元,同比减少9.86%。业内人士认为,尽管昆药集团一季度业绩出现下滑,但公司在医药行业的地位和品牌影响力依然稳固。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422100040879ee1ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422100040879ee1ed&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429619349","title":"华润三九(000999)2024年一季报点评:业绩超预期,内生增长强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2429619349","media":"浙商证券","top":-1,"share":"https://www.laohu8.com/m/news/2429619349?lang=zh_cn&edition=full","pubTime":"2024-04-22 09:20","pubTimestamp":1713748802,"startTime":"0","endTime":"0","summary":"投资要点事件: 华润三九 发布2024年一季报,报告期内实现营收72.94亿元,归母净利润13.64亿元,扣非归母净利润13.28亿元;业绩超预期。24Q1实现快速增长。毛利率为53.42%,同比-0.65pct;考虑到CHC业务毛利率高于公司平均水平,且昆药集团的毛利率较低,我们预计公司内生业务的毛利率稳中有升。公司预计2024年营业收入将实现双位数的增长,净利润将匹配营收增长水平。维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404220928148b43ab45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404220928148b43ab45&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429996551","title":"【港股通】华润医药(03320):昆药集团首季净利润1.21亿元人民币 同比减少10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429996551","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2429996551?lang=zh_cn&edition=full","pubTime":"2024-04-22 09:00","pubTimestamp":1713747638,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华润医药(03320)公布,公司附属昆药集团2024年第一季度归属于净利润1.21亿元(人民币,下同),同比减少10%;同期,实现营业收入18.53亿元,同比减少3%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/OWRlOWUwM2UzYzc0YWVmOThhNzQ1ZDFlMmFkZGIzYjY4MTQyOTUwNzU2MTA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OWRlOWUwM2UzYzc0YWVmOThhNzQ1ZDFlMmFkZGIzYjY4MTQyOTUwNzU2MTA=.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935447","is_publish_highlight":false,"gpt_icon":0},{"id":"2429607133","title":"昆药集团获东吴证券买入评级,“昆中药1381”品牌打造初见成效","url":"https://stock-news.laohu8.com/highlight/detail?id=2429607133","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2429607133?lang=zh_cn&edition=full","pubTime":"2024-04-21 12:44","pubTimestamp":1713674669,"startTime":"0","endTime":"0","summary":"4月21日,昆药集团获东吴证券买入评级,近一个月昆药集团获得9份研报关注。研报预计昆药集团在24-26年归母净利润为6.1/7.6/9.7亿元。研报认为,“昆中药1381”作为公司重点打造的精品国药平台,24Q1公司多维度打造品牌,重点产品参苓健脾胃颗粒、舒肝颗粒和香砂平胃颗粒同比增长分别为48.42%、81.72%和26.03%。此外,“777”品牌正式推出,三七全产业链高质量发展持续推进。风险提示:品牌打造不及预期,行业发生重大政策变更风险等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240421124431879bf5ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240421124431879bf5ae&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429602275","title":"东吴证券:给予昆药集团买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2429602275","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429602275?lang=zh_cn&edition=full","pubTime":"2024-04-21 12:15","pubTimestamp":1713672918,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广,向潇近期对昆药集团进行研究并发布了研究报告《2024一季报点评:“昆中药1381”品牌打造初见成效,三大黄金单品表现亮眼》,本报告对昆药集团给出买入评级,当前股价为21.39元。昆药集团投资要点事件:24Q1公司实现营业收入18.53亿元,实现归母净利润1.19亿元,实现扣非归母净利润1.13亿元;业绩符合我们预期。昆中药三大黄金单品,参苓健脾胃颗粒同比增长48.42%、舒肝颗粒同比增长81.72%,香砂平胃颗粒同比增长26.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240421121717879be5d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240421121717879be5d7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429860713","title":"东吴证券给予昆药集团买入评级 2024一季报点评 近期获11份券商研报关注 目标均价涨幅15.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429860713","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2429860713?lang=zh_cn&edition=full","pubTime":"2024-04-21 12:13","pubTimestamp":1713672796,"startTime":"0","endTime":"0","summary":"东吴证券04月21日发布研报称,给予昆药集团(600422.SH,最新价:21.39元)买入评级。评级理由主要包括:1)“昆中药1381”品牌造势初见成效,三大黄金单品表现亮眼;2)“777”品牌正式推出,三七全产业链高质量发展持续推进。风险提示:品牌打造不及预期,行业发生重大政策变更风险等。AI点评:昆药集团近一个月获得11份券商研报关注,买入5家,增持3家,平均目标价为24.6元,与最新价21.39元相比,高3.21元,目标均价涨幅15.01%。文章来源:每日经济新闻原标题:东吴证券给予昆药集团买入评级,2024一季报点评,近期获11份券商研报关注,目标均价涨幅15.01%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404211249018b40fb9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404211249018b40fb9c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428662374","title":"图解昆药集团一季报:第一季度单季净利润同比减9.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428662374","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2428662374?lang=zh_cn&edition=full","pubTime":"2024-04-20 00:51","pubTimestamp":1713545476,"startTime":"0","endTime":"0","summary":"证券之星消息,昆药集团2024年一季报显示,公司主营收入18.53亿元,同比下降3.01%;归母净利润1.19亿元,同比下降9.41%;扣非净利润1.13亿元,同比上升9.11%;负债率43.04%,投资收益77.65万元,财务费用633.98万元,毛利率41.19%。财报数据概要请见下图:以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404200103448b3be332&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404200103448b3be332&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428763445","title":"昆药集团:2024年第一季度净利润约1.19亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428763445","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2428763445?lang=zh_cn&edition=full","pubTime":"2024-04-19 18:23","pubTimestamp":1713522215,"startTime":"0","endTime":"0","summary":"每经AI快讯,昆药集团 4月19日晚间发布一季度业绩公告称,2024年第一季度营收约18.53亿元,同比减少3.01%;归属于上市公司股东的净利润约1.19亿元,同比减少9.41%;基本每股收益0.16元,同比减少5.88%。2023年1至12月份,昆药集团的营业收入构成为:药品批发与零售占比43.12%,口服剂占比39.65%,针剂占比13.75%,其他占比1.36%。昆药集团的董事长是邱华伟,男,57岁,学历背景为本科;总裁是颜炜,男,53岁,学历背景为硕士。截至发稿,昆药集团市值为162亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191832498b3ab6ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191832498b3ab6ec&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-12-06","address":"云南省昆明市五华区国家高新技术开发区科医路166号","stockEarnings":[{"period":"1week","weight":0.0523},{"period":"1month","weight":0.0563},{"period":"3month","weight":0.2375},{"period":"6month","weight":0.0798},{"period":"1year","weight":0.0854},{"period":"ytd","weight":0.0892}],"companyName":"昆药集团股份有限公司","boardCode":"AI0027","perCapita":"27440股","boardName":"医药制造业","registeredCapital":"75711万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":" 昆药集团股份有限公司主要从事药物研发、生产及销售、医药流通及大健康产业。公司新增国内授权发明专利9件、外观专利6件、PCT发明专利1件。公司“集团财务业务一体化管控能力”项目入选2022年工信部新一代信息技术与制造业融合发展试点示范名单。中国药店杂志社主办的2022-2023中国药店发展报告暨中国药店价值榜发布会上,昆药血塞通软胶囊、昆中药参苓健脾胃颗粒、昆中药舒肝颗粒、贝克诺顿阿莫西林荣获“2022年度中国药店店员推荐率最高品牌”奖项。中国中药协会主办的中国中药产业高质量发展论坛暨第三届中国中药品牌建设大会上,公司荣登“2022中成药企业百强榜”位列第13位,“2022中药上市公司TOP30”位列第12位。昆中药博物馆(非遗体验馆)荣获“春融同心·昆明市统战文化基地”称号;子公司上海昆恒医药科技有限公司认定为上海市“专精特新”中小企业。昆药血塞通软胶囊、昆中药参苓健脾胃颗粒荣获2023乌镇健康大会西湖奖,最受药店欢迎的明星单品奖。公司再次获得由国家认证认可监督管理委员会批准,中健安检测认证中心颁发的三七道地药材认证证书;子公司昆中药顺利通过知识产权管理体系贯标再认证(知识产权贯标是指贯彻《企业知识产权管理规范》(GB/T29490-2013)这一知识产权管理的国家标准),位列“2023年度云南省创新管理知识产权国际标准实施试点企业名单”。","serverTime":1714961350810,"listedPrice":10.22,"stockholders":"27586人(较上一季度增加0.21%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昆药集团(600422)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昆药集团(600422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昆药集团,600422,昆药集团股票,昆药集团股票老虎,昆药集团股票老虎国际,昆药集团行情,昆药集团股票行情,昆药集团股价,昆药集团股市,昆药集团股票价格,昆药集团股票交易,昆药集团股票购买,昆药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昆药集团(600422)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昆药集团(600422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}